Plain-English translation of NCT06915025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a major study testing whether adding a new drug called IMNN-001 to standard chemotherapy can help treat advanced ovarian, fallopian tube, or peritoneal cancer. About 500 women will be randomly assigned to receive either standard chemotherapy alone, or standard chemotherapy combined with the new medication. Researchers will track how well this medication works and how safe it is when used alongside proven cancer treatments.
Advanced ovarian cancer remains difficult to treat, and patients need better options beyond standard chemotherapy alone. This trial is designed to see whether this medication—which works through the immune system—can help the body fight cancer more effectively when combined with existing chemotherapy treatments.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to one of two groups: one receives standard chemotherapy plus the new medication, and the other receives standard chemotherapy alone. The chemotherapy ( and ) is given intravenously every 3 weeks for 6 cycles total—3 cycles before surgery and 3 cycles after. If you're in the medication group, you'll also receive IMNN-001 injected directly into the abdomen on specific days during those 6 cycles, for a total of 17 doses. After chemotherapy ends, you'll receive standard maintenance therapy. Doctors will monitor your safety closely throughout the trial with regular blood tests and check-ins.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States